Skip to main content
Clinical Trials/EUCTR2007-007156-33-GB
EUCTR2007-007156-33-GB
Active, not recruiting
Phase 1

Melatonin As A Novel Neuroprotectant in Preterm Infants- Dosage study - MIND-Melatonin Neuroprotection Dosage Study

Imperial College0 sites18 target enrollmentMarch 7, 2008

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Imperial College
Enrollment
18
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2008
End Date
February 22, 2011
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Imperial College

Eligibility Criteria

Inclusion Criteria

  • Infants born less than 31 weeks gestation who are less than 7 days old, after parental consent for participation will be included in the study.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Those with major congenital malformation, or cystic periventricular leucomalacia (cPVL) or haemorrhagic parenchymal infarcts (HPI) on cranial ultrasonography prior to enrolment will be excluded from the study

Outcomes

Primary Outcomes

Not specified

Similar Trials